Loading...
XTAI4108
Market cap96mUSD
Dec 23, Last price  
15.85TWD
1D
0.32%
1Q
-11.94%
Jan 2017
-48.12%
Name

Phytohealth Corp

Chart & Performance

D1W1MN
XTAI:4108 chart
P/E
—
P/S
19.37
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
3.32%
Rev. gr., 5y
8.62%
Revenues
162m
+19.95%
99,193,000107,904,000155,092,000177,711,000144,988,00090,732,00020,978,00025,021,00053,996,000107,483,00095,485,00091,810,000168,936,000135,465,000162,489,000
Net income
-47m
L-59.04%
-267,053,000-215,119,000-170,071,000-103,794,000-182,964,000-321,702,000-203,500,000-194,516,000-206,349,000-182,476,000-170,927,000-118,655,000-78,021,000-115,035,000-47,117,000
CFO
-55m
L-8.63%
-107,148,000-193,063,000-171,088,000-164,368,000-123,180,000-33,743,000-131,217,000-756,870,000-151,520,000-141,435,000-121,446,000-147,866,000-68,239,000-59,948,000-54,772,000
Earnings
May 28, 2025

Profile

PhytoHealth Corporation researches and develops, manufactures, and sells pharmaceutical drugs, cosmetics, Class B medicines, and supplementary foods and other related products. Its products include PG2 Lyophilized injection for the treatment of cancer related fatigue; EnerCharge, which is used in enhancing physical strength, maintaining good spirits, and enhancing health maintenance activities; ReyeasCleanse health food capsules; and EnerCharge, an energy drink. The company also offers precision medical equipment and instrument; medical diagnosis software; and computer-aided diagnosis system authorization services. PhytoHealth Corporation was incorporated in 1998 and is based in Taipei, Taiwan.
URL
https://www.phytohealth.com.tw/zh-Hant
IPO date
May 07, 2002
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
162,489
19.95%
135,465
-19.81%
168,936
84.01%
Cost of revenue
284,166
292,179
301,143
Unusual Expense (Income)
NOPBT
(121,677)
(156,714)
(132,207)
NOPBT Margin
Operating Taxes
312
(17,495)
Tax Rate
NOPAT
(121,677)
(157,026)
(114,712)
Net income
(47,117)
-59.04%
(115,035)
47.44%
(78,021)
-34.25%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,320
700,000
BB yield
-0.03%
-15.35%
Debt
Debt current
10,542
10,141
10,596
Long-term debt
45,462
50,049
51,203
Deferred revenue
Other long-term liabilities
5,011
5,011
5,003
Net debt
(533,767)
(474,640)
(482,226)
Cash flow
Cash from operating activities
(54,772)
(59,948)
(68,239)
CAPEX
(4,730)
(1,605)
(13,216)
Cash from investing activities
26,249
76,920
(581,145)
Cash from financing activities
(9,177)
(10,522)
682,226
FCF
(123,877)
(122,510)
(187,332)
Balance
Cash
1,266,096
1,360,715
1,414,715
Long term investments
(676,325)
(825,885)
(870,690)
Excess cash
581,647
528,057
535,578
Stockholders' equity
2,138,639
2,277,289
2,032,033
Invested Capital
1,722,028
1,784,594
1,888,912
ROIC
ROCE
EV
Common stock shares outstanding
198,619
198,619
195,702
Price
21.70
13.61%
19.10
-18.03%
23.30
-5.04%
Market cap
4,310,032
13.61%
3,793,623
-16.80%
4,559,856
10.15%
EV
4,119,821
3,688,504
4,485,492
EBITDA
(68,572)
(104,275)
(79,393)
EV/EBITDA
Interest
344
312
405
Interest/NOPBT